Skip to main content

Thermo Fisher to Supply Genentech with RNAi Tech for Drug Studies

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it will supply Genentech with RNAi technology for use in siRNA-based drug discovery research.
 
Under the agreement, Thermo Fisher Scientific will provide Genentech with siRNA design, stabilization, delivery, and related RNAi technologies from its RNAi Discovery and Therapeutic Services lab in Colorado.
 
The drugs Genentech is working on would silence expression of disease-related genes, which could help extend drug research efforts on targets that have so far not been successfully developed.
 
“Our work with Genentech will focus on developments that will enable in vivo target validation and potentially human therapeutic applications of RNAi technology,” Thermo Fisher Scientific VP of Global R&D Ian Jardine said in a statement.
 
Financial terms of the agreement were not released.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.